Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
62.11
+6.24 (11.17%)
At close: Mar 9, 2026, 4:00 PM EDT
63.50
+1.39 (2.24%)
After-hours: Mar 9, 2026, 5:11 PM EDT
Spruce Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
46.53
Revenue / Employee
n/a
Employees
9
Market Cap
66.78M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ImmuCell | 27.64M |
| Alterity Therapeutics | 4.43M |
| NeurAxis | 3.36M |
| BeyondSpring | 1.88M |
| ImageneBio | 800.00K |
| Rallybio | 674.00K |
| Mereo BioPharma Group | 500.00K |
| Entera Bio | 124.00K |
SPRB News
- 11 hours ago - Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates - Business Wire
- 11 hours ago - Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer - Business Wire
- 7 days ago - Spruce Biosciences to Present at Upcoming Investor Conferences in March - Business Wire
- 19 days ago - Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 20 days ago - Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Business Wire
- 4 weeks ago - Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 4 weeks ago - Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - Business Wire
- 5 weeks ago - Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - Business Wire